Celgene Higher Off Positive Phase II Sunbeam Trial Of Oral Ozanimod

By: via Benzinga
Celgene Corporation (NASDAQ: CELG) shares are trading higher by $2.00 at $120.66 in Friday's session. The catalyst for the rally is ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.